← Back to Analyst Consensus 
IPSC Buy
Century Therapeutics, Inc.
Current Price —
Implied Upside —
Analysts 12
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Nov 5, 2026 (10 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| May 27, 2026 | Mizuho | initiate | — → Outperform | — | 52% |
| Apr 21, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Jan 20, 2026 | Piper Sandler | maintain | Overweight → Overweight | $4 | 54% |
| Nov 17, 2025 | Leerink Partners | downgrade | Outperform → Market Perform | $2 | 51% |
| May 16, 2025 | Chardan Capital | maintain | Buy → Buy | $6 | 47% |
| Apr 3, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $2 | 44% |
| Mar 28, 2025 | Guggenheim | reiterate | Buy → Buy | $0 | 52% |
| Mar 24, 2025 | Chardan Capital | maintain | Buy → Buy | $7 | 47% |
| Mar 21, 2025 | Guggenheim | maintain | Buy → Buy | $5 | 52% |
| Mar 20, 2025 | Piper Sandler | maintain | Overweight → Overweight | $2 | 54% |
| Jan 22, 2025 | Guggenheim | reiterate | Buy → Buy | $0 | 52% |
| Jan 22, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $5 | 44% |
| Dec 30, 2024 | Piper Sandler | maintain | Overweight → Overweight | $4 | 54% |
| Nov 7, 2024 | Chardan Capital | maintain | Buy → Buy | $11 | 47% |
| Nov 6, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $5 | 44% |
| Aug 15, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $9 | 44% |
| Jun 17, 2024 | Piper Sandler | maintain | Overweight → Overweight | $12 | 54% |
| Jun 4, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $11 | 44% |
| May 10, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $11 | 44% |
| Apr 12, 2024 | Piper Sandler | reiterate | Overweight → Overweight | $9 | 54% |
| Mar 15, 2024 | Canaccord Genuity | maintain | Buy → Buy | $24 | 48% |
| Mar 15, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $13 | 44% |
| Dec 7, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $13 | 44% |
| Aug 28, 2023 | JP Morgan | downgrade | Overweight → Neutral | $5 | 54% |
| Aug 10, 2023 | Piper Sandler | maintain | Overweight → Overweight | $10 | 54% |
| Aug 10, 2023 | HC Wainwright & Co. | maintain | Buy → Buy | $13 | 44% |
| Aug 10, 2023 | EF Hutton | reiterate | Buy → Buy | $16 | 30% |
| Aug 10, 2023 | Chardan Capital | maintain | Buy → Buy | $17 | 47% |
| May 12, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $17 | 44% |
| Apr 17, 2023 | EF Hutton | maintain | — → Buy | $16 | 30% |
| Apr 13, 2023 | HC Wainwright & Co. | reiterate | — → Buy | $17 | 44% |
| Mar 22, 2023 | Chardan Capital | reiterate | — → Buy | $19 | 47% |
| Mar 17, 2023 | HC Wainwright & Co. | maintain | — → Buy | $17 | 44% |
| Mar 16, 2023 | EF Hutton | reiterate | — → Buy | $16 | 30% |
| Feb 9, 2023 | HC Wainwright & Co. | reiterate | — → Buy | $19 | 44% |
| Jan 6, 2023 | EF Hutton | maintain | — → Buy | $16 | 30% |
| Jan 6, 2023 | SVB Leerink | maintain | — → Outperform | $14 | — |
| Jan 6, 2023 | Piper Sandler | maintain | — → Overweight | $14 | 54% |
| Jan 6, 2023 | HC Wainwright & Co. | maintain | — → Buy | $19 | 44% |
| Jan 5, 2023 | EF Hutton | initiate | — → Buy | $18 | 30% |
| Dec 27, 2022 | Chardan Capital | initiate | — → Buy | $19 | 47% |
| Nov 14, 2022 | HC Wainwright & Co. | maintain | — → Buy | $25 | 44% |
| Oct 31, 2022 | Guggenheim | initiate | — → Buy | $15 | 52% |
| May 23, 2022 | HC Wainwright & Co. | initiate | — → Buy | $27 | 44% |
| May 17, 2022 | Piper Sandler | maintain | — → Overweight | $22 | 54% |
| Apr 29, 2022 | SVB Leerink | maintain | — → Outperform | $27 | — |
| Nov 19, 2021 | SVB Leerink | maintain | — → Outperform | $32 | — |
| Jul 13, 2021 | B of A Securities | initiate | — → Buy | $34 | 53% |
| Jul 13, 2021 | SVB Leerink | initiate | — → Outperform | $33 | — |
| Jul 13, 2021 | JP Morgan | initiate | — → Overweight | $40 | 54% |
Price Target Trend
Mar 26, 2026 Oct 26, 2026
EPS Estimates
+1y —
0q —
0y —
+1q —
Cross-Platform Signals
No cross-platform signals in the last 90 days